| Alpha HPA Limited (A4N) ORDINARY FULLY PAID |
Materials |
$1,082 |
2025 Sustainability Performance Report
|
29 Aug 2025 9:49AM |
$0.970 |
$0.745 |
fallen by
23.20%
|
|
| Accent Resources N.L. (ACS) ORDINARY FULLY PAID |
Materials |
$24 |
Response to ASX Aware Query
|
29 Aug 2025 9:49AM |
$0.006 |
$0.050 |
risen by
733.33%
|
|
ACS - Price-sensitive ASX Announcement
Full Release
Key Points
- Testwork completed on 23 July 2025.
- Awareness of results at 1pm AEST on 23 July 2025.
- No immediate announcement due to incremental and confirmatory nature.
- Results not considered to influence securities' price or value.
- Market sensitive flag used for cautious dissemination.
- Compliance with ASX Listing Rule 3.1 confirmed.
- Board authorized responses to ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Accent Resources N.L. (ACS) ORDINARY FULLY PAID |
Materials |
$24 |
Response to ASX Aware Query
|
29 Aug 2025 9:49AM |
$0.006 |
$0.050 |
risen by
733.33%
|
|
ACS - Price-sensitive ASX Announcement
Full Release
Key Points
- Metallurgical testwork results were incremental and confirmatory.
- Information did not meet the materiality threshold under Listing Rule 3.1.
- No immediate announcement was required before 4 August 2025.
- Results were marked 'market sensitive' on ASX release.
- Company maintains compliance with ASX disclosure rules.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$76 |
FY25 Results Presentation
|
29 Aug 2025 9:49AM |
$0.165 |
$0.085 |
fallen by
48.48%
|
|
| Bathurst Resources Limited (BRL) ORDINARY FULLY PAID |
Materials |
$124 |
FY25 Results presentation
|
29 Aug 2025 9:49AM |
$0.740 |
$0.515 |
fallen by
30.41%
|
|
BRL - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 results showed increased revenue and EBITDA from higher sales volumes.
- BRL's Buller and Tenas projects are key growth focuses with streamlined approvals.
- The Buller Project aims for a low-capex startup by 2027.
- The Stockton project is significant for maintaining long-term production.
- Crown Mountain project offers substantial growth optionality.
- Commitment to high-quality metallurgical coal for steelmaking.
- BRL has made significant contributions to the New Zealand economy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bathurst Resources Limited (BRL) ORDINARY FULLY PAID |
Materials |
$124 |
FY25 Results presentation
|
29 Aug 2025 9:49AM |
$0.740 |
$0.515 |
fallen by
30.41%
|
|
BRL - Price-sensitive ASX Announcement
Full Release
Key Points
- Profitable operations at BT Mining JV and Takitimu
- Successful capital raise of AUD $34 million
- Consolidated FY25 revenue of NZD $268 million
- Challenges due to Tawhai Tunnel closure
- Buller project to support production for 10+ years
- Tenas project undergoing environmental assessments
- Litigation with Talley’s Group Limited ongoing
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
Appendix 4E Preliminary Final Report FY25
|
29 Aug 2025 9:47AM |
$0.056 |
$0.022 |
fallen by
60.71%
|
|
MDR - Price-sensitive ASX Announcement
Full Release
Key Points
- MedAdvisor Limited incurred a significant loss from continuing operations at $63.3 million.
- Revenue from continuing operations dropped to $62.9 million.
- Profit from discontinuing operations was recorded.
- Significant impairment of assets noted.
- Decrease in total equity to a deficit position.
- Post reporting period sale of ANZ business reducing debt.
- Financial statements are under audit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
Appendix 4E Preliminary Final Report FY25
|
29 Aug 2025 9:47AM |
$0.056 |
$0.022 |
fallen by
60.71%
|
|
MDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant loss after income tax of $60,208,977.
- Total comprehensive income deficit of $60,599,111.
- Net liability position of $1,617,738 as of June 30, 2025.
- Revenue from health programs decreased to $63 million.
- Sale of MedAdvisor International Pty Ltd as a 'discontinuing operation'.
- Full impairment of US operations' intangible assets.
- Net cash decrease of $5.2 million, with ending cash at $10.3 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,172 |
FY2025 Full year results
|
29 Aug 2025 9:46AM |
$0.480 |
$3.650 |
risen by
660.42%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- SaaS products delivered at 388 sites globally, 60% growth year-on-year.
- Operating revenue increased to $5.9 million, up 56% from FY2024.
- FDA 510(k) submission for CT:VQ™ software.
- Strategic reseller agreement with Philips.
- Secured $10 million investment from Pro Medicus.
- Commercial progress in the U.S. and Australia.
- Focus on sustainable growth and cost efficiencies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,172 |
FY2025 Full year results
|
29 Aug 2025 9:46AM |
$0.480 |
$3.650 |
risen by
660.42%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- 4DMedical achieved significant growth in FY2025 with 388 SaaS product sites globally, up 60% year-on-year.
- The company produced over 74,000 scans in Q4 FY2025, a 35% increase quarter-on-quarter.
- 4DMedical's operating revenue for FY2025 was $5.9 million, up 56% from FY2024.
- CT:VQ™ software, a non-contrast lung imaging tool, is undergoing FDA 510(k) clearance.
- A strategic partnership with Philips aims to enhance care for veterans with respiratory diseases.
- 4DMedical secured a $10 million strategic investment from Pro Medicus.
- Contracts were signed with notable clients in the U.S. and Australia, including Integral Diagnostics and UChicago Medicine.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
TOV: BBT Panel Receives Application
|
29 Aug 2025 9:46AM |
$0.300 |
$0.170 |
fallen by
43.33%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Application by BETR Entertainment Limited regarding PointsBet Holdings Limited.
- PointsBet faces takeover offers from MIXI Australia Pty Ltd and BETR.
- BETR holds a 19.6% interest in PointsBet.
- BETR disputes PointsBet board's vesting of performance rights.
- Request for interim and final orders to influence ongoing takeover bids.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$337 |
TOV: BBT Panel Receives Application
|
29 Aug 2025 9:46AM |
$1.260 |
$0.970 |
fallen by
23.02%
|
|
PBH - Price-sensitive ASX Announcement
Full Release
Key Points
- PointsBet Holdings Limited is under two takeover offers.
- Betr holds a 19.6% interest in PointsBet.
- PointsBet board's discretion on performance rights vesting is contested.
- Betr claims the decision affects market competitiveness.
- Betr seeks to prevent further vesting and challenges new share issuance's impact on MIXI's voting power.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
TOV: BBT Panel Receives Application
|
29 Aug 2025 9:46AM |
$0.300 |
$0.170 |
fallen by
43.33%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Betr Entertainment Limited (ASX: BBT) has submitted an application to the Takeovers Panel regarding PointsBet Holdings Limited.
- PointsBet is dealing with two competing takeover offers: a cash offer from MIXI Australia and a reverse takeover offer from betr.
- Betr holds a 19.6% interest in PointsBet shares.
- PointsBet's board exercised discretion to vest Performance Rights, which betr deems inappropriate.
- Betr challenges the vesting of Performance Rights as it impacts the competitive market for PointsBet shares.
- Betr seeks interim orders to halt further vesting of options and performance rights by PointsBet.
- Betr requests final orders for the cancellation of newly issued shares and reissuance of performance rights.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$337 |
TOV: BBT Panel Receives Application
|
29 Aug 2025 9:46AM |
$1.260 |
$0.970 |
fallen by
23.02%
|
|
PBH - Price-sensitive ASX Announcement
Full Release
Key Points
- Takeovers Panel received an application from betr Entertainment Limited regarding PointsBet Holdings Limited.
- PointsBet is subject to two competing takeover offers: from MIXI Australia Pty Ltd and betr.
- Concerns raised about PointsBet board accelerating the vesting of performance rights.
- betr claims the board's actions result in unfair competitive conditions.
- betr seeks orders to prevent further acceleration of options or rights and to not count the newly issued shares towards MIXI's voting power.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barrow Hanley Global Share Fund (Managed Fund) (GLOB) |
Financials |
$544 |
Quarterly Portfolio Disclosure - June 2025
|
29 Aug 2025 9:44AM |
$4.800 |
$5.180 |
risen by
7.92%
|
|
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$26 |
Appendix 4E and Annual Report
|
29 Aug 2025 9:44AM |
$0.064 |
$0.070 |
risen by
9.38%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for the year: $7.2 million
- Total assets: $9.9 million
- Total liabilities: $3.7 million
- Decrease in cash and cash equivalents to $4.5 million
- Issued 43 million shares raising $4.3 million
- Contributed equity at year-end: $33.8 million
- Major shareholders include Capital Property Corporation and Nabelle Pty Ltd
- Unutilized tax losses: $13.8 million
- Details of financial instruments and lease liabilities
- Key management personnel remuneration and shareholdings
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$26 |
Appendix 4E and Annual Report
|
29 Aug 2025 9:44AM |
$0.064 |
$0.070 |
risen by
9.38%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- BCAL Diagnostics Limited launched its first commercial product, BREASTESTplus™, in the Australian market.
- The product addresses the diagnostic challenge of detecting tumors in women with high breast density.
- 107 tests were sold by June 30, 2025, reflecting commercial traction and clinical validation.
- The company established a strategic partnership with Cancer Care Associates and the Sydney Breast Clinic.
- BCAL Diagnostics has filed a third Australian patent and expanded its intellectual property portfolio.
- The company closed FY2025 with a cash balance of $4.5 million.
- Revenue primarily comprises the R&D tax offset with an estimated claim of $2.5 million for 2025.
- BCAL Diagnostics is focusing on expanding BREASTESTplus™ in Australia and preparing for the US market entry.
- BCAL recorded a net loss of $7,241,035 for the year ended June 30, 2025.
- The company incorporated a wholly owned subsidiary in North Carolina, USA, for R&D expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jayride Group Limited (JAY) ORDINARY FULLY PAID |
Industrials |
$9 |
Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
JAY - Price-sensitive ASX Announcement
Full Release
Key Points
- Jayride Group Limited reported a total revenue of $2,423,121 for the financial year ending 30 June 2025.
- The company experienced a comprehensive loss of $5,725,322 for the year.
- Net cash used in operating activities amounted to $1,474,395.
- There was a significant decrease in net liability equity, totaling $(6,380,722) at the end of the financial year.
- The basic and diluted loss per share was reported as (1.05) cents.
- Capitalised technology costs faced a complete write-down, resulting in impairment costs of $2,898,346.
- The company issued shares to raise capital, resulting in a total issued capital of $47,502,291.
- Jayride Group Limited had significant operating costs, including advertising and marketing expenses totaling $795,584.
- Current liabilities exceeded current assets, highlighting financial challenges for the company.
- The company did not incur any income tax expenses for the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jayride Group Limited (JAY) ORDINARY FULLY PAID |
Industrials |
$9 |
Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
JAY - Price-sensitive ASX Announcement
Full Release
Key Points
- The total revenue for Jayride Group Limited decreased by 55.5% to $2,423,121 compared to the previous year.
- The loss after income tax for the year ended 30 June 2025 was $5,725,322, a decrease of 30.7% from the previous year.
- Net tangible assets per ordinary security were recorded at -0.45 cents.
- No dividends were paid, recommended, or declared during the current or previous financial period.
- The company issued 1,427,179,974 ordinary shares, with a significant increase due to the conversion of convertible notes.
- Impairment testing led to the complete write-down of technology assets, totaling an impairment recognition of $2,898,346 in the previous financial year.
- The weighted average number of ordinary shares increased significantly, impacting the loss per share calculations.
- The financial statements are in the process of being audited, with an anticipated unqualified audit opinion including a going concern paragraph.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$76 |
FY25 Results
|
29 Aug 2025 9:42AM |
$0.165 |
$0.085 |
fallen by
48.48%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,172 |
Appendix 4E - Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.480 |
$3.650 |
risen by
660.42%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating revenue increased by 56% primarily from SaaS.
- Net loss improved to $30.1 million from the previous year.
- Other income primarily from government grants and R&D incentives.
- Imbio acquisition contingent consideration remeasurement led to $7.3 million in gains.
- Slight increase in operating expenses due to commercialization investments.
- Share placements and funding agreements to support growth and regulatory efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,172 |
Appendix 4E - Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.480 |
$3.650 |
risen by
660.42%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating revenue increased by 56% to $5.9 million.
- Net loss reported at $30.1 million, improving from the previous year.
- Significant SaaS revenue contribution.
- Acquisition of Imbio Inc. and related earn-outs recognized.
- Capital raised through share placements and purchase plans.
- Secured a $10 million funding with Pro Medicus Limited.
- Government grants supporting R&D activities.
- Focus on regulatory clearance for medical technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Ethical SRI Fund (Managed Fund) (GIVE) |
Financials |
$13 |
Quarterly Portfolio Disclosure - June 2025
|
29 Aug 2025 9:41AM |
$3.210 |
$2.840 |
fallen by
11.53%
|
|
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$76 |
FY25 Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:39AM |
$0.165 |
$0.085 |
fallen by
48.48%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Bubs Australia Limited reported a profit of AUD 5.54 million for the financial year ending 30 June 2025.
- Total comprehensive income for FY25 was AUD 5.17 million, accounting for other comprehensive loss.
- Net cash from operating activities was positive at AUD 6.13 million, a significant improvement from the previous year's outflow.
- Issued capital remained unchanged at AUD 356.76 million as of 30 June 2025.
- The company focused on improving cash flow and reducing liabilities, with total liabilities dropping significantly from AUD 29.88 million to AUD 14.69 million.
- Share-based payments were utilized, with a reserve increase from AUD 12.26 million to AUD 12.69 million.
- The net assets of the company increased from AUD 36.87 million to AUD 42.48 million.
- Foreign currency translation reserve showed a loss, highlighting some impact from currency fluctuations.
- Receipts from customers rose to AUD 103.75 million, indicating increased sales and market activity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flynn Gold Limited (FG1) ORDINARY FULLY PAID |
Materials |
$13 |
$130,000 in Grant Funding for Drilling at Mangana and Henty
|
29 Aug 2025 9:39AM |
$0.027 |
$0.022 |
fallen by
18.52%
|
|
FG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Flynn Gold Limited (ASX: FG1) secured $130,000 in grant funding from the Tasmanian Government's Exploration Drilling Grant Initiative (EDGI).
- The funding is aimed at supporting drill testing at the Mangana Project and the Henty South Project in Tasmania.
- Mangana Project involves drilling two diamond drill holes totaling 400 meters beneath the historic Golden Entrance mine.
- Henty South Project includes a plan to drill one 500-meter diamond hole targeting a coincident gravity and IP anomaly.
- The Mangana Project targets high-grade gold beneath historic workings that have not been drill tested for a century.
- The EDGI program is a Tasmanian State Government initiative to stimulate greenfield exploration.
- The Mangana Goldfield produced approximately 6,700 ounces of gold from 1852 to 1910.
- The Golden Entrance mine was historically the richest producer in the Mangana Goldfield.
- Preparatory activities for drilling at both projects are currently underway.
- Flynn Gold owns and controls the exploration licenses through its subsidiary, Kingfisher Exploration Pty Ltd.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
